Anosmia is a recognized symptom of COVID-19, with anywhere between 30% to 80% of sufferers reporting loss of smell.
Pfizer released data from several studies showing that nirmatrelvir, the active main protease inhibitor of the company’s antiviral combination therapy Paxlovid (nirmatrelvir/ritonavir), is effective against the Omicron variant of SARS-CoV-2. Additionally, a study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
Speaking with French newspaper Le Figaro, Pfizer Chief Executive Officer Albert Bourla said he believes the world will “return to normal life” sometime during the spring of 2022.
A review of recently published scientific studies includes a detailed imaging analysis to determine how SARS-CoV-2, the virus that causes Covid-19, reprograms infected cells.
According to a study published in the journal Science Advances, an international team of researchers led by neuroscientists at Harvard Medical School uncovered which olfactory cell types are most vulnerable to infection by SARS-CoV-2, which causes Covid-19.
